Table 2

Comparison of characteristics of patients with SLE with or without fatigue

CharacteristicsPatients with fatigue
(n=257)
Patients without fatigue
(n=93)
P value
Age, years, median (IQR 25–75)43 (35–54), n=25741 (31–47), n=930.03
Sex (female)230 (89), n=25782 (88), n=930.70
Anxiety97 (42), n=2329 (11), n=84<0.0001
Depression34 (15), n=2242 (2), n=800.002
PGA, median (IQR 25–75)0.5 (0.2–1), n=2570.3 (0.2–0.95), n=930.004
SELENA-SLEDAI, median (IQR 25–75)4 (1.5–6), n=2572 (2–5), n=930.43
Hydroxychloroquine198 (79), n=24974 (81), n=910.76
Any GC173 (67), n=25752 (56), n=930.06
GC >10 mg/day50 (20), n=25015 (17), n=890.64
Any IS114 (44), n=25737 (40), n=930.46
  • P values in bold indicate significance.

  • All results are presented as n (%) unless stated otherwise.

  • ‘n=’ means number of patients with available data.

  • IS agents include azathioprine or methotrexate or mycophenolate or cyclophosphamide or rituximab or belimumab.

  • GC, glucocorticoids; IQR 25–75, 25th–75th percentile IQR; IS, immunosuppressive agent; PGA, Physician Global Assessment; SELENA, Safety of Estrogens in Lupus Erythematosus National Assessment; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.